Riskpilot← Back to searchSign inGet full accessAranda Pharma Partners Oy
OYDissolvedY-tunnus 2905307-7Annankatu 12Fund management activities · NACE 6630Est. 20180 employees
Revenue 2024
EUR 0
EBITDA margin
—
+48% vs 2023
Equity ratio
99.3%
Financial strength
Net profit 2024
EUR -977
+49% vs 2023
| Revenue | EUR 0 | — |
| EBITDA | EUR -965 | +48% |
| Net profit | EUR -977 | +49% |
| Total assets | EUR 672K | +1% |
| Equity | EUR 667K | +1% |
| Employees | 0 | — |
Legal name
Aranda Pharma Partners Oy
Y-tunnus number
2905307-7
Legal form
Osakeyhtiö
NACE code
6630 · Fund management activities
Founded
23. maaliskuuta 2018
Share capital
EUR 2 506
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsenet ja varajäsenet kaksi yhdessä
Company purpose
Yhtiö omistaa ja hallitsee arvopapereita ja muita rahoitusinstrumentteja Aranda Pharma Oy:ssä.
Address
Annankatu 12
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | −0 | −0 |
| EBITDA | −0 | −0 | −1 | −2 | −1 |
| Depreciation & amort. | — | — | — | −0 | −0 |
| EBIT | −0 | −0 | −1 | −2 | −1 |
| Net financials | — | — | — | −0 | −0 |
| Profit before tax | −0 | −0 | −1 | −2 | −1 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −0 | −0 | −1 | −2 | −1 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 612 | 647 | 648 | 664 | 672 |
| Equity | 612 | 647 | 646 | 661 | 667 |
| Long-term debt | — | — | — | 0 | 0 |
| Short-term debt | 0 | 0 | 2 | 3 | 5 |
| Total debt | 0 | 0 | 2 | 3 | 5 |
EBITDA margin
-96500.0%
This company
15.8%
Market median
-610859% vs market
20202024
Equity ratio
99.3%
This company
38.2%
Market median
+160% vs market
20202024
Return on equity
-0.1%
This company
18.4%
Market median
-101% vs market
20202024
Net profit margin
-97700.0%
This company
8.1%
Market median
-1206273% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
GJ Deputy Member | Deputy Member | 2025 |
| Former (2) | ||
AM Deputy Member | Deputy Member | 2019 – 2025 |
KI Deputy Member | Deputy Member | 2018 – 2019 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2018 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Aranda Pharma Partners Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Greete Johanna Pöder | Deputy Member | 0 companies |
| Anna Maria Bernitz | Deputy Member | 0 companies |
| Kaija Ilona Teräkivi | Deputy Member | 0 companies |
| Tommi Juha Äijälä | Board of Directors | 0 companies |